Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

Data ReadoutpositiveICOTYDEPositive

AI Analysis

Summary

Johnson & Johnson announced positive 2-year durability data for ICOTYDE (icotrokinra), an oral IL-23R targeted peptide, demonstrating sustained skin clearance in difficult-to-treat plaque psoriasis with a favorable safety profile, supporting its use as a first-line systemic therapy.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

2-year durability data showing sustained skin clearance with favorable safety profile; 60% of scalp psoriasis patients and 89% of genital psoriasis patients achieved site-specific complete clearance

Importance:7/10

Sentiment:

0.85

dermatologypsoriasisIL-23R inhibitororal therapyclinical datadurability

Related Companies

$JNJ

Read the original article

Published by PR Newswire Biotech on October 2, 2026 10:00 AM

Read Original

Johnson &amp; Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

Summary

Clinical Trial Data

Outcome Details

Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy